AtriCure, Inc. $ATRC Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 64.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 186,965 shares of the medical device company’s stock after purchasing an additional 73,468 shares during the period. Squarepoint Ops LLC owned about 0.38% of AtriCure worth $6,127,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ameritas Investment Partners Inc. grew its position in shares of AtriCure by 6.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock valued at $162,000 after buying an additional 312 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in AtriCure by 5.4% in the second quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock valued at $246,000 after acquiring an additional 385 shares during the period. Captrust Financial Advisors grew its holdings in shares of AtriCure by 8.9% during the second quarter. Captrust Financial Advisors now owns 7,299 shares of the medical device company’s stock valued at $239,000 after purchasing an additional 598 shares during the last quarter. Scotia Capital Inc. grew its holdings in shares of AtriCure by 1.7% during the second quarter. Scotia Capital Inc. now owns 37,220 shares of the medical device company’s stock valued at $1,220,000 after purchasing an additional 611 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in shares of AtriCure by 1.6% during the 2nd quarter. California State Teachers Retirement System now owns 45,001 shares of the medical device company’s stock worth $1,475,000 after purchasing an additional 691 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ATRC has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price objective on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.22.

Insider Buying and Selling

In other news, insider Justin J. Noznesky sold 5,166 shares of AtriCure stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total value of $192,640.14. Following the transaction, the insider directly owned 78,798 shares of the company’s stock, valued at $2,938,377.42. This trade represents a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Maggie Yuen sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $35.72, for a total transaction of $107,160.00. Following the sale, the director owned 11,371 shares in the company, valued at $406,172.12. This represents a 20.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 18,166 shares of company stock valued at $676,378. 3.50% of the stock is owned by corporate insiders.

AtriCure Price Performance

NASDAQ ATRC opened at $42.38 on Monday. The firm has a market capitalization of $2.11 billion, a PE ratio of -69.47 and a beta of 1.47. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.85. AtriCure, Inc. has a 12 month low of $28.29 and a 12 month high of $43.11. The company’s 50 day simple moving average is $35.83 and its 200 day simple moving average is $34.72.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.10. The company had revenue of $134.27 million for the quarter, compared to analysts’ expectations of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. The business’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, equities research analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.